XLRN - Acceleron Pharma Inc...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $127.90 | Open | $127.06 |
| Volume | 987.2K | Market Cap | 7.744B |
| Yield | Last Dividend |
| Acceleron Reports Fourth Quarter and Ful... | 02/25/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and comm... | |
| Acceleron Pharma numbers crunched for yo... | 02/24/21 |
| Acceleron Pharma announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| The Daily Biotech Pulse: Aridis To Study... | 02/23/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acc... | |
| Acceleron to Participate in Two Upcoming... | 02/23/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and comme... | |
| Acceleron to Webcast Fourth Quarter and ... | 02/17/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, Februar... | |
| Health Canada Approves REBLOZYL?? (luspa... | 02/16/21 |
| MONTREAL--(BUSINESS WIRE)--Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL?? (lus... | |
| DelveInsight Analysts Expect Beta-Thalas... | 02/08/21 |
| LAS VEGAS , Feb. 8, 2021 /PRNewswire/ -- DelveInsight's Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta T... | |
| Acceleron to Participate in the 39th Ann... | 01/04/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron???s President and Chief Executive O... | |
| Morgan Stanley Stick to Their Buy Rating... | 12/16/20 |
| Morgan Stanley Stick to Their Buy Rating for Acceleron Pharma | |
| Acceleron Receives Orphan Designation fr... | 12/14/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and comm... | |
| IBM ??? International Inclusion Physique... | 12/13/20 |
| IBM - International Inclusion Physique Myositis Market 2020 ??? 2028 large progress with Acceleron Pharma, KPI Therapeutics, Milo Biotechnology LLC, N... | |
| Oppenheimer Stick to Their Buy Rating fo... | 11/16/20 |
| Oppenheimer Stick to Their Buy Rating for Acceleron Pharma | |
| Acceleron Presents Preliminary Interim D... | 11/13/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commer... | |
| Acceleron Reports Third Quarter 2020 Ope... | 11/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and comme... | |
| Acceleron Announces Third Quarter 2020 R... | 11/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and comme... | |
| Acceleron Announces REBLOZYL?? (luspater... | 11/04/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commer... | |
| Acceleron to Webcast Third Quarter 2020 ... | 10/26/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, Novembe... | |
| The Daily Biotech Pulse: J&J Pauses Coro... | 10/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X... | |
| The Daily Biotech Pulse: Amag Spikes On ... | 10/01/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Ac... | |
| The Daily Biotech Pulse: Eton Snags Seco... | 09/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Ac... | |
| Hormone Refractory Prostate Cancer (HRPC... | 09/30/20 |
| Global Hormone Refractory Prostate Cancer (HRPCA) Market Report The ???Global Hormone Refractory Prostate Cancer (HRPCA) Market Insights, Forecast to ... | |
| Acceleron to Host Webcast Outlining the ... | 09/17/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commer... | |
| Acceleron Appoints Laura J. Hamill to it... | 09/16/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commerc... | |
| Acceleron Reports Second Quarter 2020 Op... | 08/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and comme... | |
| Acceleron Announces Second Quarter 2020 ... | 08/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and comme... | |
| Acceleron to Webcast Second Quarter 2020... | 07/27/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August ... | |
| The Daily Biotech Pulse: Mixed Tidings F... | 07/24/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Acceleron Pharma Inc ??? | |
| Acceleron Announces Pricing of Public Of... | 06/30/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commer... | |
| Acceleron readies $400M stock offering (... | 06/29/20 |
| Acceleron Pharma (NASDAQ:XLRN) initiates a $400M public offering of common stock. Price, volume and terms have yet to be announced. | |
| Acceleron Announces Proposed Public Offe... | 06/29/20 |
| Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development and commercialization of TGF-beta superfamily | |
| Buy rating | 03/01/21 |
| Citigroup maintains Buy rating and raises Price Target from $137.00 to $171.00 | |
| Strong Buy rating | 02/26/21 |
| SVB Leerink maintains Outperform rating and raises Price Target from $138.00 to $148.00 | |
| Strong Buy rating | 02/26/21 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $135.00 to $145.00 | |
| Strong Buy rating | 02/26/21 |
| Piper Sandler maintains Overweight rating and raises Price Target from $130.00 to $143.00 | |
| Strong Buy rating | 01/29/21 |
| JP Morgan maintains Overweight rating and raises Price Target from $133.00 to $153.00 | |
| Buy rating | 01/19/21 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $148.00 to $168.00 | |
| rating | 01/19/21 |
| Raymond James maintains Strong Buy rating and raises Price Target from $155.00 to $160.00 | |
| Strong Buy rating | 12/16/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $130.00 to $135.00 | |
| Date | 2021-02-25 (AMC) | Est. (EPS/Rev.) | ($0.59)/ 32.31M |
| Actual (EPS/Rev.) | $-0.95/ $25.87 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
